SG10201604654RA - Biomarkers and combination therapies using oncolytic virus and immunomodulation - Google Patents
Biomarkers and combination therapies using oncolytic virus and immunomodulationInfo
- Publication number
- SG10201604654RA SG10201604654RA SG10201604654RA SG10201604654RA SG10201604654RA SG 10201604654R A SG10201604654R A SG 10201604654RA SG 10201604654R A SG10201604654R A SG 10201604654RA SG 10201604654R A SG10201604654R A SG 10201604654RA SG 10201604654R A SG10201604654R A SG 10201604654RA
- Authority
- SG
- Singapore
- Prior art keywords
- immunomodulation
- biomarkers
- combination therapies
- oncolytic virus
- oncolytic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261590441P | 2012-01-25 | 2012-01-25 | |
US201261637191P | 2012-04-23 | 2012-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201604654RA true SG10201604654RA (en) | 2016-07-28 |
Family
ID=47754947
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913784YA SG10201913784YA (en) | 2012-01-25 | 2013-01-25 | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
SG10201604654RA SG10201604654RA (en) | 2012-01-25 | 2013-01-25 | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
SG11201404313YA SG11201404313YA (en) | 2012-01-25 | 2013-01-25 | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913784YA SG10201913784YA (en) | 2012-01-25 | 2013-01-25 | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201404313YA SG11201404313YA (en) | 2012-01-25 | 2013-01-25 | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
Country Status (12)
Country | Link |
---|---|
US (3) | US10238698B2 (zh) |
EP (2) | EP3578198A1 (zh) |
JP (3) | JP2015508156A (zh) |
KR (1) | KR102081567B1 (zh) |
CN (1) | CN104427992B (zh) |
AU (2) | AU2013211871B2 (zh) |
BR (1) | BR112014018331A8 (zh) |
CA (1) | CA2862390A1 (zh) |
DK (1) | DK2806883T3 (zh) |
HK (2) | HK1204577A1 (zh) |
SG (3) | SG10201913784YA (zh) |
WO (1) | WO2013112942A1 (zh) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2529747T (pt) | 2005-12-02 | 2018-05-09 | Icahn School Med Mount Sinai | Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações |
EP2376535B9 (en) | 2008-12-09 | 2017-09-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
ES2550179T3 (es) | 2009-02-05 | 2015-11-05 | Icahn School Of Medicine At Mount Sinai | Virus quiméricos de la enfermedad de Newcastle y usos de los mismos |
AU2013214776B2 (en) | 2012-02-02 | 2017-11-09 | Board Of Regents, The University Of Texas System | Adenoviruses expressing heterologous tumor-associated antigens |
US20150044224A1 (en) * | 2012-03-02 | 2015-02-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Materials and methods for differential treatment of cancer |
WO2013169971A1 (en) * | 2012-05-10 | 2013-11-14 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
EA201590451A1 (ru) * | 2012-08-30 | 2016-05-31 | Эмджен Инк. | Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки |
CA2905272A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
WO2014186761A2 (en) * | 2013-05-17 | 2014-11-20 | The Board Of Trustes Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-cd47 agent |
CN104415335A (zh) * | 2013-09-02 | 2015-03-18 | 北京中康万达医药科技有限公司 | 体内个体化系统免疫治疗方法和装置 |
CA2931322A1 (en) * | 2013-11-22 | 2015-05-28 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
JP6857498B2 (ja) * | 2014-02-27 | 2021-04-14 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 癌を処置するための併用方法 |
EP2942629A1 (en) * | 2014-05-08 | 2015-11-11 | Universität Würzburg | Predictive markers for successful cancer immunotherapy |
US20170115291A1 (en) * | 2014-05-28 | 2017-04-27 | Dana-Farber Cancer Institute, Inc. | Activating JAK Kinase Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response |
AU2015335607B2 (en) * | 2014-10-24 | 2020-04-23 | Calidi Biotherapeutics (Nevada), Inc. | Combination immunotherapy approach for treatment of cancer |
US11060150B2 (en) | 2015-03-17 | 2021-07-13 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating cancer |
TWI820377B (zh) | 2015-05-07 | 2023-11-01 | 美商艾吉納斯公司 | 抗ox40抗體及其使用方法 |
EP3302541A4 (en) * | 2015-06-03 | 2018-12-05 | Aelan Cell Technologies Inc. | Methods and devices for the production and delivery of beneficial factors from stem cells |
EP3217993A1 (en) | 2015-07-20 | 2017-09-20 | Virttu Biologics Limited | Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood |
EP3327137B1 (en) * | 2015-07-22 | 2020-12-09 | National University Corporation Tottori University | Host regulation factor for enhancing proliferation and propagation of vaccinia virus |
US10105436B2 (en) | 2015-08-11 | 2018-10-23 | Calidi Biotherapeutics, Inc. | Smallpox vaccine for cancer treatment |
WO2017037298A1 (en) | 2015-09-04 | 2017-03-09 | Aslan Pharmaceuticals Pte Limited | A combination therapy comprising varlitinib and an anticancer agent |
WO2017062615A2 (en) * | 2015-10-08 | 2017-04-13 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
EP3362091A4 (en) * | 2015-10-15 | 2019-04-24 | Duke University | COMBINATION THERAPY |
CN106591361A (zh) * | 2015-10-20 | 2017-04-26 | 钱文斌 | 一种重组痘溶瘤病毒及其构建方法和应用 |
MX2018006477A (es) | 2015-12-02 | 2018-09-03 | Agenus Inc | Anticuerpos y metodos de uso de estos. |
DK3400293T4 (da) * | 2016-01-08 | 2023-08-28 | Replimune Ltd | Modificeret onkolytisk virus |
EP3193173A1 (en) * | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Serological autoantibodies as biomarker for colorectal cancer |
FI127460B (en) * | 2016-01-15 | 2018-06-29 | Targovax Oy | COMBINATION OF ADENOVIRUS AND CHEMOTHERAPY AGENTS FOR CANCER CARE |
WO2017127707A1 (en) * | 2016-01-21 | 2017-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
CN105603085B (zh) * | 2016-01-29 | 2019-01-29 | 北京泱深生物信息技术有限公司 | 椎间盘退行性病变的诊治靶标 |
US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
CN114028549A (zh) * | 2016-02-19 | 2022-02-11 | 伊玛提克斯生物技术有限公司 | 用于nhl和其他癌症免疫治疗的新型肽和肽组合物 |
JP7208492B2 (ja) * | 2016-03-10 | 2023-01-19 | シージー オンコロジー, インコーポレイテッド | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
WO2017176289A1 (en) * | 2016-04-08 | 2017-10-12 | Celgene Corporation | Uses of lenalidomide and car t-cells |
GB201608918D0 (en) * | 2016-05-20 | 2016-07-06 | Aslan Pharmaceuticals Pte Ltd | Method |
EP3463405A4 (en) * | 2016-05-27 | 2020-02-26 | DNAtrix, Inc. | ADENOVIRUS AND IMMUNOMODULATORY POLYTHERAPY |
US11865149B2 (en) | 2016-06-17 | 2024-01-09 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES |
WO2018022831A1 (en) * | 2016-07-28 | 2018-02-01 | Musc Foundation For Research Development | Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors |
WO2018071824A1 (en) * | 2016-10-13 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature |
US20190275092A1 (en) | 2016-11-01 | 2019-09-12 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
AU2017375958A1 (en) * | 2016-12-12 | 2019-07-04 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
KR20190098215A (ko) | 2016-12-21 | 2019-08-21 | 멤젠 엘엘씨 | 무장된 복제-가능 종양 분해 아데노바이러스 |
WO2018132571A1 (en) * | 2017-01-13 | 2018-07-19 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
CN108341818A (zh) * | 2017-01-21 | 2018-07-31 | 南京华威医药科技开发有限公司 | 巴瑞克替尼及其磷酸盐的新晶型及其制备方法 |
CN108338994A (zh) * | 2017-01-25 | 2018-07-31 | 杭州康万达医药科技有限公司 | 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用 |
CN110520539A (zh) * | 2017-02-08 | 2019-11-29 | 米特拉处方诊断公司 | 预测抗癌药的临床结果的方法 |
WO2018152095A1 (en) * | 2017-02-14 | 2018-08-23 | Celgene Corporation | Treatment of cancer with smg1-inhibitors |
US11338003B2 (en) | 2017-04-14 | 2022-05-24 | Cg Oncology, Inc. | Methods of treating bladder cancer with an oncolytic virus |
US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
JP7365345B2 (ja) * | 2018-01-17 | 2023-10-19 | イーライ リリー アンド カンパニー | インターロイキン-19を標的とする化合物および方法 |
CN108414660B (zh) * | 2018-03-08 | 2020-03-20 | 中国药科大学 | 一组与肺癌早期诊断相关的血浆代谢小分子标志物的应用 |
CN110527696A (zh) * | 2018-06-13 | 2019-12-03 | 中山大学 | 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用 |
KR102091567B1 (ko) * | 2018-06-15 | 2020-03-20 | 인하대학교 산학협력단 | 오스테오폰틴 단백질 단편을 유효성분으로 함유하는 뇌손상 예방 또는 치료용 약학 조성물 |
CN110755619A (zh) * | 2018-07-27 | 2020-02-07 | 复旦大学 | 一种人疱疹病毒裂解复制激活的宿主标志物及其用途 |
CN108998529A (zh) * | 2018-08-30 | 2018-12-14 | 上海交通大学医学院附属上海儿童医学中心 | 肺腺癌检测试剂盒及检测tulp2基因甲基化水平的方法 |
US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
EP3876951A1 (en) * | 2018-11-06 | 2021-09-15 | Calidi Biotherapeutics, Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
WO2020197505A1 (en) * | 2019-03-27 | 2020-10-01 | Singapore Health Services Pte Ltd | Biomarker with therapeutic implications for peritoneal carcinomatosis |
CA3134957A1 (en) * | 2019-03-28 | 2020-10-01 | Mayo Foundation For Medical Education And Research | Ifn.beta. as a pharmacodynamic marker in vsv-ifn.beta.-nis oncolytic therapy |
KR102199141B1 (ko) * | 2019-05-03 | 2021-01-06 | 사회복지법인 삼성생명공익재단 | 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법 |
AU2020325825A1 (en) | 2019-08-05 | 2022-03-17 | Mesoblast International Sarl | Cellular compositions comprising viral vectors and methods of treatment |
CN110687281B (zh) * | 2019-08-26 | 2023-05-23 | 中国医学科学院肿瘤医院 | Pd-l1自身抗体在肿瘤预后评估中的应用 |
CN114630683A (zh) * | 2019-08-29 | 2022-06-14 | 拜耳诺克斯有限公司 | 包含痘苗病毒和粒细胞生成抑制剂作为活性成分的用于治疗癌症的药物组合物 |
US20220381769A1 (en) * | 2019-09-23 | 2022-12-01 | Sillajen, Inc. | Immune Assay for Monitoring Response to Oncolytic Vaccinia Virus and Uses Thereof |
CN111337678B (zh) * | 2020-02-21 | 2023-06-06 | 杭州凯保罗生物科技有限公司 | 与肿瘤免疫治疗效果相关的生物标志物及其应用 |
US11324750B2 (en) | 2020-04-09 | 2022-05-10 | Children's Hospital Medical Center | Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection |
WO2021206766A1 (en) | 2020-04-09 | 2021-10-14 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
WO2021225421A1 (ko) * | 2020-05-08 | 2021-11-11 | 주식회사 루닛 | 면역 항암제에 대한 반응을 예측하는 방법 및 시스템 |
KR102591696B1 (ko) * | 2020-05-08 | 2023-10-19 | 주식회사 루닛 | 병리 슬라이드 이미지에 대한 면역 표현형과 연관된 정보를 제공하는 방법 및 장치 |
JP2023525465A (ja) * | 2020-05-08 | 2023-06-16 | ルニット インコーポレイテッド | 病理スライドイメージに対する免疫表現型と関連付けられた情報を提供する方法及び装置 |
CN111579788A (zh) * | 2020-05-29 | 2020-08-25 | 郑州大学 | 一种高灵敏肿瘤标志物EPHA2的Simoa试剂盒及其应用 |
KR20230046298A (ko) | 2020-08-10 | 2023-04-05 | 메조블라스트 인터내셔널 에스에이알엘 | 세포 조성물 및 치료 방법 |
CN112345755B (zh) * | 2020-09-23 | 2023-06-16 | 杭州凯保罗生物科技有限公司 | 乳腺癌的生物标志物及其应用 |
JP2024500575A (ja) * | 2020-12-22 | 2024-01-09 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | がんの早期かつ正確な検出のための、血液ベースのタンパク質バイオマーカーパネル |
WO2023107878A1 (en) * | 2021-12-06 | 2023-06-15 | Oncorus, Inc. | Compositions and methods of seneca valley virus (svv) related cancer therapy |
WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
DE69534791T2 (de) | 1994-11-28 | 2006-08-31 | Cell Genesys, Inc., South San Francisco | Vektoren zur gewebsspezifischen replikation |
DE69628744D1 (de) | 1995-04-17 | 2003-07-24 | Univ Texas System Austin Board | Adenovirus helfervirus system |
US20030026789A1 (en) | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
US6080578A (en) | 1996-12-31 | 2000-06-27 | Onyx Pharmaceuticals, Inc. | Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia |
US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
WO1998039467A2 (en) | 1997-03-03 | 1998-09-11 | Calydon, Inc. | Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof |
US6096718A (en) | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
CA2351587A1 (en) | 1998-11-18 | 2000-05-25 | Canji, Inc. | Viral vectors with late transgene expression |
GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
WO2000067576A1 (en) | 1999-05-12 | 2000-11-16 | The Uab Research Foundation | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
WO2000075292A1 (en) | 1999-06-08 | 2000-12-14 | Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
WO2001023004A1 (en) | 1999-09-30 | 2001-04-05 | The Trustees Of The University Of Pennsylvania | Replication selective adenoviruses for use in cancer therapy |
WO2001028569A1 (en) | 1999-10-15 | 2001-04-26 | Canji, Inc. | Targeted vectors |
US6740525B2 (en) | 2000-02-09 | 2004-05-25 | Genvec, Inc. | Adenoviral capsid containing chimeric protein IX |
US6756044B1 (en) | 2000-02-09 | 2004-06-29 | Genvec, Inc. | Antigenic complexes and methods |
US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
US20030211477A1 (en) | 2002-04-05 | 2003-11-13 | Holmes Kathryn V. | Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening |
EP2457587A1 (en) | 2003-06-27 | 2012-05-30 | Amgen Fremont Inc. | Anitbodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
US20070134202A1 (en) * | 2003-10-15 | 2007-06-14 | The New Industry Reserch Organization | Cancer gene therapeutic drug |
WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
ES2463442T3 (es) * | 2004-03-31 | 2014-05-28 | Tomoki Todo | Potenciador de la actividad anticancerosa en terapia viral y método de prevención o de tratamiento del cáncer |
MX2007000457A (es) | 2004-07-13 | 2007-04-17 | Univ British Columbia | Inhibidores de indoleamina 2,3-dioxigenasa (ido). |
ES2457067T3 (es) | 2005-05-06 | 2014-04-24 | Providence Health System | Proteína de fusión OX40-inmunoglobulina trimérica y métodos de uso |
HUE026039T2 (en) * | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies programmed for death ligand 1 (PD-L1) |
JP2009504687A (ja) | 2005-08-31 | 2009-02-05 | オンコリティクス バイオテク,インコーポレーテッド | 新生物に関する免疫系による認識のインビボでの増強のための、腫瘍崩壊ウイルスおよび免疫賦活剤による処置 |
WO2007103825A2 (en) * | 2006-03-02 | 2007-09-13 | The Board Of Regents Of The University Of Texas System | Combination therapy with oncolytic adenovirus |
WO2009117656A2 (en) | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
KR20110050529A (ko) | 2008-08-25 | 2011-05-13 | 앰플리뮨, 인크. | Pd-1 길항제의 조성물 및 사용 방법 |
EP2379586B1 (en) | 2008-12-22 | 2016-11-02 | Targovax Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
CN101607985B (zh) | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体,包含其的组合物,及其用途 |
CA2761438C (en) | 2009-05-15 | 2017-12-12 | University Health Network | Compositions and methods for treating hematologic cancers targeting the sirp.alpha.-cd47 interaction |
US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
EP2266588A1 (en) * | 2009-06-04 | 2010-12-29 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Method for cancer therapy based on co-administration of a parovirus and a cytokine |
CN104826106B (zh) * | 2009-09-30 | 2019-01-11 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
JP2013512251A (ja) * | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
EP2407177A1 (en) | 2010-07-13 | 2012-01-18 | Institut Gustave Roussy | Adenovirus vaccine vectors |
EP2383577A1 (en) * | 2010-04-30 | 2011-11-02 | Deutsches Krebsforschungszentrum | Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy |
US9314516B2 (en) | 2010-05-04 | 2016-04-19 | Cassian Yee | Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses |
TW201840336A (zh) | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
WO2013043569A1 (en) * | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
AU2013214776B2 (en) | 2012-02-02 | 2017-11-09 | Board Of Regents, The University Of Texas System | Adenoviruses expressing heterologous tumor-associated antigens |
SG11201510430RA (en) | 2013-06-18 | 2016-01-28 | Dnatrix Inc | Treatment of brain cancer with oncolytic adenovirus |
-
2013
- 2013-01-25 AU AU2013211871A patent/AU2013211871B2/en not_active Ceased
- 2013-01-25 SG SG10201913784YA patent/SG10201913784YA/en unknown
- 2013-01-25 SG SG10201604654RA patent/SG10201604654RA/en unknown
- 2013-01-25 BR BR112014018331A patent/BR112014018331A8/pt not_active Application Discontinuation
- 2013-01-25 WO PCT/US2013/023304 patent/WO2013112942A1/en active Application Filing
- 2013-01-25 EP EP19170696.9A patent/EP3578198A1/en not_active Withdrawn
- 2013-01-25 CN CN201380010639.1A patent/CN104427992B/zh active Active
- 2013-01-25 CA CA2862390A patent/CA2862390A1/en not_active Abandoned
- 2013-01-25 DK DK13706770.8T patent/DK2806883T3/da active
- 2013-01-25 SG SG11201404313YA patent/SG11201404313YA/en unknown
- 2013-01-25 KR KR1020147023448A patent/KR102081567B1/ko active IP Right Grant
- 2013-01-25 JP JP2014554887A patent/JP2015508156A/ja active Pending
- 2013-01-25 US US14/374,619 patent/US10238698B2/en active Active
- 2013-01-25 EP EP13706770.8A patent/EP2806883B1/en active Active
-
2015
- 2015-06-01 HK HK15105220.4A patent/HK1204577A1/zh unknown
- 2015-09-14 HK HK15108961.1A patent/HK1208349A1/zh unknown
-
2018
- 2018-03-13 AU AU2018201776A patent/AU2018201776A1/en not_active Abandoned
- 2018-11-09 JP JP2018211406A patent/JP2019066482A/ja active Pending
-
2019
- 2019-03-05 US US16/293,624 patent/US20190269744A1/en not_active Abandoned
-
2020
- 2020-06-30 US US16/917,170 patent/US11065285B2/en active Active
-
2021
- 2021-03-08 JP JP2021035972A patent/JP2021103174A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN104427992B (zh) | 2017-12-19 |
AU2013211871A1 (en) | 2014-08-14 |
DK2806883T3 (da) | 2019-07-22 |
CA2862390A1 (en) | 2013-08-01 |
WO2013112942A1 (en) | 2013-08-01 |
SG11201404313YA (en) | 2014-10-30 |
US10238698B2 (en) | 2019-03-26 |
AU2013211871B2 (en) | 2017-12-14 |
KR102081567B1 (ko) | 2020-02-26 |
AU2018201776A1 (en) | 2018-04-05 |
US20190269744A1 (en) | 2019-09-05 |
JP2015508156A (ja) | 2015-03-16 |
US11065285B2 (en) | 2021-07-20 |
HK1208349A1 (zh) | 2016-03-04 |
EP2806883A1 (en) | 2014-12-03 |
CN104427992A (zh) | 2015-03-18 |
SG10201913784YA (en) | 2020-03-30 |
KR20150008846A (ko) | 2015-01-23 |
US20200330533A1 (en) | 2020-10-22 |
HK1204577A1 (zh) | 2015-11-27 |
EP3578198A1 (en) | 2019-12-11 |
BR112014018331A8 (pt) | 2017-07-11 |
JP2019066482A (ja) | 2019-04-25 |
BR112014018331A2 (zh) | 2017-06-20 |
US20140377221A1 (en) | 2014-12-25 |
EP2806883B1 (en) | 2019-04-24 |
JP2021103174A (ja) | 2021-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1208349A1 (zh) | 生物標誌物及使用溶瘤病毒和免疫調節劑的組合療法 | |
HK1211851A1 (zh) | 抗登革病毒抗體和其用途 | |
HK1204809A1 (zh) | 自動駕駛儀及其方法 | |
HK1202545A1 (zh) | 新型二氮雜螺環烷烴和氮雜螺環烷烴 | |
HK1207092A1 (zh) | 抗- 抗體及其用途 | |
EP2855662A4 (en) | RECOMBINANT MICROORGANISMS AND USES THEREOF | |
EP2859089A4 (en) | RECOMBINANT MICROORGANISMS AND USES THEREOF | |
EP2855690A4 (en) | RECOMBINANT MICROORGANISMS AND USES THEREOF | |
SG11201501254RA (en) | Recombinant microorganisms and uses therefor | |
GB201201100D0 (en) | Polypeptides and methods | |
HK1210949A1 (zh) | 組合及其用途 | |
HK1205523A1 (zh) | 抗-大-內皮素- 抗體及其用途 | |
HK1199269A1 (zh) | 抗- 的抗體及其用途 | |
GB201321144D0 (en) | Improved oncolytic viruses | |
GB201202016D0 (en) | Noise and projection fairing | |
EP2938415A4 (en) | MATERIALS AND METHOD | |
ZA201501658B (en) | Ventilator and blade therefor | |
EP2920312A4 (en) | ONCOLYTIC HSV1 VECTORS AND METHODS OF USING SAME | |
GB201214769D0 (en) | Methodsa and peptides | |
GB201222541D0 (en) | Kiddibidet and pottibidet | |
IL218974A0 (en) | Conaction bitwen coutch and playels | |
GB201202021D0 (en) | Co-sleeper and breastfeeder | |
GB201210303D0 (en) | Polypeptides and methods | |
GB201202945D0 (en) | Novel cancer therapies and methods |